Infectious Disease
Mycobacterium Avium Complex Disease
11
Pipeline Programs↗
0
Active Trials↗
9
Companies Involved↗
Mycobacterium avium complex disease is an emerging landscape with 11 programs across 9 companies. The most active players are Agouron Pharmaceuticals, Horizon Therapeutics Ireland DAC, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 1 therapy is approved with 7 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 23
Phase 37
Approved1
Analysis
Trial Status
5
clinical trials
Completed4 · 80%
Terminated1 · 20%
Clinical Trials
Trial Activity
Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease
Completed·—·Phase 2/3·NCT03672630·474 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)